Jaguar Health is a pharmaceuticals company that develops plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal distress, such as chronic, debilitating diarrhea. Co.'s subsidiary, Napo Pharmaceuticals, Inc. (Napo), develops and commercializes proprietary plant-based human pharmaceuticals. Napo's marketed drug Mytesi (crofelemer 125 mg delayed-release tablets) is an oral botanical drug product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Co.'s Canalevia-CA1 (crofelemer delayed-release tablets) drug is an oral plant-based prescription product to treat chemotherapy-induced diarrhea in dogs. The JAGX stock yearly return is shown above.
The yearly return on the JAGX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the JAGX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|